FOXO4 -DRI peptide preparation 10mg/bottle core information
Pharmaceutical -grade peptide preparations | FOXO4-DRI (cell senescence inhibitor )
Amino acid sequence : Ac-GRKKRRQRRRPPQCLPPLIVRLHSTRC-OH
Molecular weight : approximately 3.2 kDa
Specifications : 10mg/bottle
Dosage form : Lyophilized powder for injection
Appearance : White or off-white freeze-dried powder
Purity : ≥98% (HPLC analysis)
Core Effects
FOXO4-DRI is a peptide formulation that targets cellular senescence . Due to its unique mechanism of selectively inducing apoptosis in senescent cells , it is widely used in anti-aging research, tissue function repair, and intervention of age-related diseases .
✅ Precise targeting mechanism of action :
Interfering with FOXO4-p53 interaction : Specific blocking of FOXO4 binding to p53 in senescent cells
Selective apoptosis induction : Promoting p53 to enter the cell nucleus and initiating the apoptosis program of senescent cells
Maintain normal cells : Does not affect the physiological functions of normal healthy cells
✅ Physiological effects characteristics :
Eliminating senescent cells : Effectively reducing the accumulation of senescent cells in tissues and organs
Improve tissue function : restore the regeneration and repair capacity of aging tissues
Delaying the aging process : Alleviating age-related decline in physiological functions
✅ Clinical application potential :
Skin rejuvenation : Improve skin elasticity and reduce wrinkles
Motor Function Enhancement : Improve muscle strength and endurance
Organ function maintenance : Supports the healthy function of organs such as liver and kidney
Usage Protocol
1. Reconstitution Method :
Dilution options :
Sterile water for injection or normal saline is recommended
Avoid using diluents containing preservatives to ensure peptide stability
Preparation steps :
Disinfect the surface of the rubber stopper (wipe with 75% alcohol cotton pad)
Slowly inject 1-2 ml of diluent (final concentration 5-10 mg/ml)
Gently rotate the bottle until it is completely dissolved, avoiding violent shaking to produce bubbles
The prepared solution should be a clear liquid without suspended matter.
2. Injection dosage regimen :
Commonly used doses studied :
Animal studies: 0.5-2 mg/kg body weight, 2-3 times per week
Preclinical data: Human equivalent dose based on body surface area conversion
Injection route :
Subcutaneous injection : Abdomen, thighs and other fat-rich areas
Intravenous injection : requires professional medical personnel to perform
Local injection : local administration of drugs around the target tissue
3. Recommended usage :
Initial dose :
Start with a low dose and observe individual response
Recommended starting dose: 0.1-0.2 mg/kg
Maintenance dose :
Gradually adjust according to tolerance
Typical maintenance dose: 0.3-0.5 mg/kg
Treatment cycle :
Short-term intervention: 4-8 weeks per cycle
Long-term maintenance: Repeat treatment cycles every 3-6 months
Storage Protocol
1. Storage of unreconstituted product :
Temperature requirements :
Long-term storage: Store frozen at -20°C (up to 24 months)
Short-term use: Refrigerate at 2-8°C (use within 6 months)
Protect from light and moisture :
Store in original packaging away from light and direct ultraviolet rays
Place desiccant to prevent moisture and deterioration
Avoid repeated freezing and thawing, and use in aliquots
2. Storage after preparation :
Refrigerate :
Temperature: 2-8°C Refrigerate
Expiration date: Use within 7 days after preparation
Note: Mark the preparation date and time
Check before use :
Solution clarity: Discard if turbid or precipitated
Color change: Yellowing or discoloration indicates degradation
Aseptic operation: Sterilize the rubber stopper before each extraction
3. Transport Conditions :
Cold Chain Transport :
Transport temperature: -20°C frozen transport or 2-8°C refrigerated transport
Packaging requirements: Special cold chain box + sufficient ice packs
Time requirement: Delivery within 48 hours to ensure activity
Acceptance Criteria :
Check the ice pack: Make sure it is not completely melted
Product appearance: The powder should be uniform white
Packaging integrity: no damage, no contamination
Important Notes
1. Safe use :
Taboo groups :
Pregnant and lactating women are prohibited from using
Use with caution in patients with autoimmune diseases
Contraindicated in patients with severe hepatic and renal insufficiency
Adverse Reactions :
Injection site reactions (redness, swelling, pain) may occur
Rare systemic allergic reactions
Long-term safety data are limited
2. Usage suggestions :
Professional guidance : Use under the guidance of a doctor or professional
Individualized approach : Adjust dosage based on age and health status
Regular evaluation : Regular evaluation of efficacy and safety during treatment
Why choose FOXO4-DRI ?
Innovative mechanism : The first peptide formulation targeting cellular senescence
Precise targeting : Selectively eliminate senescent cells and protect normal cells
Broad prospects : Huge potential in the field of anti-aging and age-related diseases
Conclusion
FOXO4-DRI peptide preparations are innovative therapies targeting cellular aging . Through scientific formulation and standardized storage and use , they offer new insights into anti-aging research. Choosing us will provide you with high-purity products, professional guidance, and comprehensive service .
Need technical support or usage guidance ?
Welcome to contact our professional team to provide you with detailed solutions!
Need anything, please contact us
|
|
+852 4671 8216 |
|
Telegram |
Allenraws |
|
|
Allenraws810@gmail.com |

Hot Tags: foxo4 10mg/vial peptides freeze-dried powder, China foxo4 10mg/vial peptides freeze-dried powder manufacturers, suppliers, factory, AOD9604 Ideal For Competition Prep Peak Weeks, ace 031 1mg, buy aod 9604 pills, peptide cjc ipamorelin, Alternative to GHRP 6, hgh ipamorelin

